Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIB1 plus pembrolizumab in advanced unresectable melanoma
2018-002844-10Phase 2Unknown
- Sponsor
- Scancell
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SCIB1 and pembrolizumab in melanoma, sponsored by Scancell. Primary endpoint: Safety and tolerability of SCIB1 in patients receiving pembrolizumab. Status: unknown.
02
Drugs
SCIB1pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-002844-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002844-10.